CALVIN TRAN: Open Payments
NPI 1407376775 · BRADENTON, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,293 in 172 payments from 21 companies in 2025. Trend: 2023 $1,690 · 2024 $2,681 · 2025 $3,293
Food & beverage: $3,293
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $320 |
| Neurocrine BioSciences, Inc. | 14 | $302 |
| Corium, LLC | 12 | $255 |
| Noven Therapeutics, LLC | 14 | $244 |
| Lundbeck LLC | 10 | $240 |
| Vanda Pharmaceuticals Inc. | 10 | $232 |
| Tris Pharma Inc | 16 | $200 |
| ABBVIE INC. | 12 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $193 |
| Teva Pharmaceuticals USA, Inc. | 11 | $160 |
Products named: REXULTI, ARISTADA, INGREZZA, Azstarys, Xelstrym, VRAYLAR, CAPLYTA, FANAPT.
Industry payments across FL — which companies pay providers there.
